Eli Lilly and Incyte’s Rheumatoid arthritis gains first approval from EU Commision

Eli Lilly’s Olumiant has achieved its first regulatory approval with a nod from the European Commission to treat moderate-to-severe active rheumatoid arthritis. The decision allows the treatment to be used either as a monotherapy or in combination with methotrexate to treat adult patients with the condition who have responded inadequately or are intolerant to one

Continue Reading

Pfizer’s Xeljanz Approved by US FDA

Pfizer are celebrating today after US regulators approved their rheumatoid arthritis drug, Xeljanz, yesterday.  The treatment is the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis. The US Food and Drug Administration (FDA) have given the green light to Xeljanz (tofacitinib) 5mg twice-daily for the medication of adults with moderately to severely

Continue Reading